Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "trial"

2295 News Found

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline
News | March 26, 2026

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances


Alkem Laboratories launches affordable semaglutide injection in India
News | March 26, 2026

Alkem Laboratories launches affordable semaglutide injection in India

Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800


FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
News | March 25, 2026

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'

New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis


Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
Clinical Trials | March 24, 2026

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials


Japan okays new long-acting eye drug
News | March 24, 2026

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients


Bayer wins world-first nod in Japan for low-dose MRI contrast agent
News | March 24, 2026

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging


Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
Clinical Trials | March 24, 2026

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

The company plans to submit the vaccine for regulatory review


Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
News | March 23, 2026

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety


Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
R&D | March 23, 2026

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses